Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | FADS1 | O60427 | 1/20 | 0.42 |
| ▸ | COMT | P21964 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19370620 | 0.86 | DDB1 (0.55) | P2RX7ALDH1A1LMNACYP2A13MAPT | |
| SCHEMBL11799876 | 0.77 | ALDH1A1 (0.62) | P2RX7ALDH1A1LMNACYP2A13MAPT | |
| SCHEMBL30798198 | 0.74 | KMT2A (0.57) | P2RX7ALDH1A1LMNACYP2A13MAPT | |
| SCHEMBL25834261 | 0.73 | DDB1 (0.71) | MAPTSIGMAR1POLBKDM4E | |
| SCHEMBL10493799 | 0.72 | P2RX7 (0.47) | P2RX7ALDH1A1LMNACYP2A13MAPT | |
| SCHEMBL22672202 | 0.70 | P2RX7 (0.46) | P2RX7ALDH1A1LMNACYP2A13MAPT | |
| SCHEMBL26017324 | 0.70 | P2RX7 (0.50) | P2RX7ALDH1A1LMNACYP2A13MAPT | |
| SCHEMBL25834300 | 0.69 | CRBN (0.40) | P2RX7LMNACXCR3 | |
| SCHEMBL25952623 | 0.68 | GAA (0.48) | ALDH1A1SIGMAR1POLBSMN1; SMN2TDP1 | |
| SCHEMBL4134218 | 0.67 | P2RX7 (0.45) | P2RX7ALDH1A1LMNACYP2A13MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | P2RX7 3064/4885ALDH1A1 4309/4885LMNA 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.